keyword
MENU ▼
Read by QxMD icon Read
search

ACEI

keyword
https://www.readbyqxmd.com/read/29218625/diuretic-or-beta-blocker-for-hypertensive-patients-already-receiving-acei-arb-and-calcium-channel-blocker
#1
Min-Shan Tsai, Chao-Hsiun Tang, Chia-Ying Lin, Po-Ya Chuang, Nai-Chuan Chen, Chien-Hua Huang, Wei-Tien Chang, Tzung-Dau Wang, Ping-Hsun Yu, Wen-Jone Chen
BACKGROUND: In patients already receiving combination of angiotensin-converting enzyme inhibitor (ACEI)/angiotensin receptor blocker (ARB) and calcium channel blocker (CCB), whether the choice of additional diuretic or beta-blocker affects the cardiovascular and cerebrovascular outcomes remains unclear. METHODS: A total of 13,551 patients who were concurrently receiving three anti-hypertensive agents of different classes through outpatient clinics during 2004-2006 were identified from the National Health Insurance Research Database of Taiwan...
December 8, 2017: Cardiovascular Drugs and Therapy
https://www.readbyqxmd.com/read/29216260/angiotensin-receptor-blockers-are-associated-with-lower-mortality-than-ace-inhibitors-in-predialytic-stage-5-chronic-kidney-disease-a-nationwide-study-of-therapy-with-renin-angiotensin-system-blockade
#2
Chih-Ching Lin, Yu-Te Wu, Wu-Chang Yang, Min-Juei Tsai, Jia-Sin Liu, Chi-Yu Yang, Szu-Yuan Li, Shuo-Ming Ou, Der-Cherng Tarng, Chih-Cheng Hsu
Dual renin angiotensin system (RAS) blockade using angiotensin-receptor blockers (ARBs) in combination with angiotensin converting enzyme inhibitors (ACEIs) is reported to improve proteinuria in both diabetic and non-diabetic patients. However, its renoprotective effect and safety remain uncertain in patients with advanced chronic kidney disease (CKD). From January 1, 2000 through June 30, 2009, we enrolled 14,117 pre-dialytic stage 5 CKD patients with serum creatinine >6mg/dL and hematocrit <28% under the treatment with erythropoiesis stimulating agents and RAS blockade...
2017: PloS One
https://www.readbyqxmd.com/read/29216228/primary-prevention-of-myocardial-infarction-with-angiotensin-converting-enzyme-inhibitors-and-angiotensin-receptor-blockers-in-hypertensive-patients-with-rheumatoid-arthritis-a-nationwide-cohort-study
#3
Ting-Tse Lin, Cho-Kai Wu, Min-Tsun Liao, Yao-Hsu Yang, Pau-Chung Chen, Dong-Feng Yeih, Lian-Yu Lin
BACKGROUND: Rheumatoid arthritis (RA) is regarded as a high risk factor for myocardial infarction. Hypertension is a major modifiable risk factor contributing to increased risk of myocardial infarction (MI). Dual blood pressure (BP)-lowering and anti-inflammatory effect of renin-angiotensin-system (RAS) inhibitors may possess protective effect from MI in RA population. However, treatment of hypertension with RAS inhibitors and MI in RA population remains unclear. METHODS: We investigated whether RAS blockade could decrease risk of incident MI in hypertensive patients with RA...
2017: PloS One
https://www.readbyqxmd.com/read/29208203/effects-of-adding-rheum-officinale-to-angiotensin-converting-enzyme-inhibitors-or-angiotensin-receptor-blockers-on-renal-function-in-patients-with-chronic-renal-failure-a-meta-analysis-of-randomized-controlled-trials%C3%A2
#4
Yue Yang, Ye-Ping Ma, Zheng Zhang, Pei-Lin Dai, Ping Li, Wen-Ge Li
OBJECTIVE: Rheum officinale is a traditional medicinal herb used widely in China to treat chronic renal failure, but the proof of evidence-based medicine is poor. This meta-analysis aims to assess the benefits of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) supplemented with Rheum officinale for delaying the progression of chronic renal failure. MATERIALS AND METHODS: The MEDLINE, EMBASE, Cochrane Library, SinoMed, Chinese National Knowledge Infrastructure, Wanfang, and VIP databases were searched to identify studies published before September 2016 that investigated the effects of ACEI/ARB plus the Chinese patented medicine Rheum (CPM-Rheum) compared to ACEI/ARB alone in lowering serum creatinine (SCr) and blood urea nitrogen (BUN) levels in chronic renal failure patients...
December 6, 2017: Clinical Nephrology
https://www.readbyqxmd.com/read/29206698/surgery-and-discontinuation-of-angiotensin-converting-enzyme-inhibitors-current-perspectives
#5
Nikola Bradic, Zdenko Povsic-Cevra
PURPOSE OF REVIEW: The current article reviews the current evidence for continuing or discontinuing angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) during the perioperative period. RECENT FINDINGS: In patients undergoing treatment of hypertension with ACEIs or ARBs, there are both benefits associated with continuing these medications during the perioperative period and higher risk for perioperative hypotension and its complications...
December 4, 2017: Current Opinion in Anaesthesiology
https://www.readbyqxmd.com/read/29206036/the-design-and-development-of-a-potent-and-selective-novel-diprolyl-derivative-that-binds-to-the-n-domain-of-angiotensin-i-converting-enzyme
#6
Stephen Fienberg, Gyles E Cozier, K Ravi Acharya, Kelly Chibale, Edward D Sturrock
Angiotensin-I converting enzyme (ACE) is a Zinc metalloprotease consisting of two catalytic domains (N- and C-). Most clinical ACE inhibitor(s) (ACEi) have been shown to inhibit both domains non-selectively resulting in adverse effects such as cough and angioedema. Selectively inhibiting the individual domains is likely to reduce these effects and potentially treat fibrosis in addition to hypertension. ACEi from GVK Biosciences database were inspected for possible N-domain selective binding patterns. From this set, a diprolyl chemical series was modelled using docking simulations...
December 5, 2017: Journal of Medicinal Chemistry
https://www.readbyqxmd.com/read/29192956/initial-clinical-experience-with-the-first-drug-sacubitril-valsartan-in-a-new-class-arnis-in-patients-with-heart-failure-with-reduced-left-ventricular-ejection-fraction-in-poland
#7
Marta Kałużna-Oleksy, Jolanta Kolasa, Jacek Migaj, Agnieszka Pawlak, Małgorzata Lelonek, Jadwiga Nessler, Ewa Straburzyńska-Migaj
Sacubitril/valsartan is the first drug from a new class of angiotensin receptor neprilisin inhibitors (ARNIs) recommended in the new European Society of Cardiology's guidelines instead of ACEIs, or ARBs (angiotensin receptor antagonists) used if ACEIs are not tolerated, for further reduction in the risk of hospitalisation or death in outpatients with HFrEF if symptoms continue despite optimal treatment with ACEIs/ARBs, betablockers and MRAs (mineralocorticoid antagonists). The aim of this paper is to present the initial experience with regard to the effectiveness, tolerance and safety of sacubitril/valsartan in the outpatient cardiology practice in Poland...
December 1, 2017: Kardiologia Polska
https://www.readbyqxmd.com/read/29185789/integrated-treatment-of-prostaglandin-e1-and-angiotensin-converting-enzyme-inhibitor-in-diabetic-kidney-disease-rats-possible-role-of-antiapoptosis-in-renal-tubular-epithelial-cells
#8
Yaru Mou, Yaqin Zhang, Congcong Guo, Junyu Zhao, Zhongwen Zhang, Xiaojun Zhou, Jianjun Dong, Lin Liao
To investigate the therapeutic mechanisms underlying prostaglandin E1 (PGE1) and angiotensin-converting enzyme inhibitor (ACEI) on reducing urinary protein in diabetic kidney disease (DKD). DKD rats were established and randomly divided into four groups: PGE1 (10 μg/kg/day) (P group), ACEI (10 mg/kg/day) (A group), combination of PGE1 with ACEI treatment (P + A group), and saline treatment group (DKD group). Untreated rats were used as normal control (N group). Urinary albumin, endothelin-1 (ET-1), angiotensin II (AngII), TUNEL assay, Masson's trichrome staining, and immunohistochemistry staining for CD68 were evaluated in all groups...
November 29, 2017: DNA and Cell Biology
https://www.readbyqxmd.com/read/29185253/cost-effectiveness-of-sacubitril-valsartan-in-chronic-heart-failure-patients-with-reduced-ejection-fraction
#9
Zanfina Ademi, Alena M Pfeil, Elizabeth Hancock, David Trueman, Rola Haroun Haroun, Celine Deschaseaux, Matthias Schwenkglenks
AIMS: We aimed to assess the cost effectiveness of sacubitril/valsartan compared to angiotensin-converting enzyme inhibitors (ACEIs) for the treatment of individuals with chronic heart failure and reduced-ejection fraction (HFrEF) from the perspective of the Swiss health care system. METHODS: The cost-effectiveness analysis was implemented as a lifelong regression-based cohort model. We compared sacubitril/valsartan with enalapril in chronic heart failure patients with HFrEF and New York-Heart Association Functional Classification II-IV symptoms...
November 29, 2017: Swiss Medical Weekly
https://www.readbyqxmd.com/read/29179525/aliskiren-therapy-in-hypertension-and-cardiovascular-disease-a-systematic-review-and-a-meta-analysis
#10
REVIEW
Shufang Fu, Xin Wen, Fei Han, Yin Long, Gaosi Xu
The efficacy and safety of aliskiren combination therapy with angiotensin converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in patients with hypertension and cardiovascular disease remains attractive attention. We searched the Cochrane Central Register, the Clinical Trials Registry, EMBASE, MEDLINE and PubMed for relevant literatures up to January 2017. A total of 13 randomized controlled trials (RCTs) with 12222 patients were included in this study, and the combined results indicated that aliskiren in combination therapy with ACEIs or ARBs had remarkable effects in reducing systolic blood pressure (SBP) [weighted mean differences (WMD), -4...
October 24, 2017: Oncotarget
https://www.readbyqxmd.com/read/29177815/a-database-cohort-study-to-assess-the-risk-of-angioedema-among-patients-with-heart-failure-initiating-angiotensin-converting-enzyme-inhibitors-in-the-usa
#11
Thy P Do, Arpamas Seetasith, Rossella Belleli, Raymond G Schlienger, Stefano Corda, Chakkarin Burudpakdee, Hendrik J Streefkerk, Sigrid Behr
INTRODUCTION: Real-world evidence on the risk of angioedema associated with angiotensin-converting enzyme inhibitors (ACEIs) in patients with heart failure (HF) is scarce. OBJECTIVE: This non-interventional study aimed to estimate the incidence of and risk factors for angioedema in patients with HF initiating an ACEI in real-world practice. METHODS: This was a retrospective cohort study using claims data from the PharMetrics Plus database, supplemented with consumer health data, from 1 January 2007 to 31 March 2015...
November 24, 2017: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://www.readbyqxmd.com/read/29175038/renin-angiotensin-system-blockade-does-not-attenuate-abdominal-aortic-aneurysm-growth-rupture-rate-or-perioperative-mortality-after-elective-repair
#12
REVIEW
Konrad Salata, Muzammil Syed, Mohamad A Hussain, Rachel Eikelboom, Charles de Mestral, Subodh Verma, Mohammed Al-Omran
OBJECTIVE: The objective of this study was to summarize the literature regarding the effects of renin-angiotensin system blockade (RASB) using angiotensin-converting enzyme inhibitors (ACEis) or angiotensin receptor blockers (ARBs) on human abdominal aortic aneurysm (AAA) growth, rupture, and perioperative mortality. METHODS: We conducted a systematic review in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Our review protocol was registered at the International Prospective Register of Systematic Reviews (CRD42016054082)...
November 23, 2017: Journal of Vascular Surgery
https://www.readbyqxmd.com/read/29172824/aliskiren-and-valsartan-in-combination-is-a-promising-therapy-for-hypertensive-renal-injury-in-rats
#13
Hala Salah Abdel Kawy
Neither ACEI nor ARBs completely repress the RAAS. Aliskiren is a newer agent that inhibits renin. However, it increases the biosynthesis and secretion of renin and prorenin, that might induce renal tissue damage. This study was conducted to investigate the renoprotective effects of aliskiren and valsartan the ARB, either alone or in combination, on hypertensive nephropathy induced by L-NAME. Aliskiren (50 mg/kg/daily i.p.), valsartan (10 mg/kg daily i.p.) alone or in half dose combination were administered with L-NAME (30-40 mg daily in drinking water) for 8 weeks...
November 27, 2017: Clinical and Experimental Hypertension: CHE
https://www.readbyqxmd.com/read/29172402/olmesartan-is-not-associated-with-the-risk-of-enteropathy-a-korean-nationwide-observational-cohort-study
#14
Seng Chan You, Hojun Park, Dukyong Yoon, Sooyoung Park, Boyoung Joung, Rae Woong Park
Background/Aims: Olmesartan, a widely used angiotensin II receptor blocker (ARB), has been linked to sprue-like enteropathy. No cases of olmesartan-associated enteropathy have been reported in Northeast Asia. We investigated the associations between olmesartan and other ARBs and the incidence of enteropathy in Korea. Methods: Our retrospective cohort study used data from the Korean National Health Insurance Service to identify 108,559 patients (58,186 females) who were initiated on angiotensin converting enzyme inhibitors (ACEis), olmesartan, or other ARBs between January 2005 and December 2012...
November 27, 2017: Korean Journal of Internal Medicine
https://www.readbyqxmd.com/read/29168689/in-hospital-prescriptions-of-secondary-prevention-medications-for-post-acute-coronary-syndrome-patients-in-south-korea%C3%A2
#15
Han-Bin Kang, Minwook Choi, Sang Gyeong Yoon, Young Seuk Cho, Nam Kyung Je
BACKGROUND: Optimal medical therapy and the management of cardiac risk factors are crucial for the secondary prevention of acute coronary syndrome (ACS). However, there have been reports on the underutilization of secondary-prevention medications for ACS. This study aimed to investigate adherence of in-hospital prescriptions to clinical practice guidelines for the secondary prevention of ACS using real-world data. MATERIALS AND METHODS: We collected information on ACS patients from national insurance claims data...
November 23, 2017: International Journal of Clinical Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/29161689/interactive-effectiveness-of-angiotensin-converting-enzyme-inhibitors-and-angiotensin-receptor-blockers-or-their-combination-on-survival-of-hemodialysis-patients
#16
Ryo Kido, Tadao Akizawa, Masafumi Fukagawa, Yoshihiro Onishi, Takuhiro Yamaguchi, Shunichi Fukuhara
BACKGROUND: Does the use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers individually or as a combination confer a survival benefit in hemodialysis patients? The answer to this question is yet unclear. METHODS: We performed a case-cohort study using data from the Mineral and Bone Disorder Outcomes Study for Japanese CKD stage 5D patients (MBD-5D), a 3-year multicenter prospective case-cohort study, including 8,229 hemodialysis patients registered from 86 facilities in Japan...
November 21, 2017: American Journal of Nephrology
https://www.readbyqxmd.com/read/29158710/the-impact-of-pharmacists-providing-direct-patient-care-as-members-of-interprofessional-teams-on-diabetes-management
#17
Osamah M Alfayez, Majed S Al Yami, Maryam T Fazel
The purpose of this study was to evaluate the impact of pharmacist providing direct patient care as a member of interprofessional team on diabetes management. This study is a retrospective chart review of diabetes patients seen by a pharmacist in an endocrinology clinic affiliated with an academic medical center. The following patient outcomes were recorded pre and post the pharmacist intervention: glycemic control as measured by change in hemoglobin A1c (HbA1c), change in systolic blood pressure (SBP) and diastolic blood pressure (DBP), statin use, and use of angiotensin converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs)...
November 2017: Saudi Pharmaceutical Journal: SPJ: the Official Publication of the Saudi Pharmaceutical Society
https://www.readbyqxmd.com/read/29153114/cost-effectiveness-analyses-of-antihypertensive-medicines-a-systematic-review
#18
REVIEW
Chanhyun Park, Guijing Wang, Jefferey M Durthaler, Jing Fang
CONTEXT: Hypertension affects one third of the U.S. adult population. Although cost-effectiveness analyses of antihypertensive medicines have been published, a comprehensive systematic review across medicine classes is not available. EVIDENCE ACQUISITION: PubMed, Embase, Cochrane Library, and Health Technology Assessment were searched to identify original cost-effectiveness analyses published from 1990 through August 2016. Results were summarized by medicine class: angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), calcium channel blockers (CCBs), thiazide-type diuretics, β-blockers, and others...
December 2017: American Journal of Preventive Medicine
https://www.readbyqxmd.com/read/29150471/biochemical-monitoring-after-initiation-of-aldosterone-antagonist-therapy-in-users-of-renin-angiotensin-system-blockers-a-uk-primary-care-cohort-study
#19
Sarah-Jo Sinnott, Kathryn E Mansfield, Morten Schmidt, Krishnan Bhaskaran, Liam Smeeth, Dorothea Nitsch, Laurie A Tomlinson
OBJECTIVE: To determine the frequency of biochemical monitoring after initiation of aldosterone antagonists(AA) in patients also using angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEI/ARB). SETTING: UK primary care. PARTICIPANTS: ACEI/ARB users who initiated AA between 2004 and 2014. OUTCOMES: We calculated the proportions with: (1) biochemical monitoring ≤2 weeks post initiation of AA, (2) adverse biochemical values ≤2 months (potassium ≥6 mmol/L, creatinine ≥220 µmol/L and ≥30% increase in creatinine from baseline) and (3) discontinuers of AA in those with an adverse biochemical value...
November 16, 2017: BMJ Open
https://www.readbyqxmd.com/read/29146378/association-of-p-wave-duration-index-with-atrial-fibrillation-recurrence-after-cryoballoon-catheter-ablation
#20
Onur Kaypakli, Hasan Koca, Durmuş Yıldıray Şahin, Sefa Okar, Fadime Karataş, Mevlüt Koç
AIM: We aimed to investigate the relationship between the recurrence of AF and P wave duration index (PWDI) in patients with nonvalvular PAF. METHODS: We included 114 patients who underwent cryoballoon catheter ablation with the diagnosis of paroxysmal atrial fibrillation (PAF) (55 male, 59 female; mean age 55.5±10,9years). PWDI was calculated by dividing the Pwd by the PR interval in DII lead of 12‑lead ECG. Patients had regular follow-up visits with 12-lead ECG, medical history and clinical evaluation...
October 9, 2017: Journal of Electrocardiology
keyword
keyword
35813
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"